Patents by Inventor Kazuya Koumoto
Kazuya Koumoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11384159Abstract: Provided are a ?-1,3-1,6-glucan powder having high solubility in water, a glucan-containing composition using the powder or the like, a method for producing the ?-1,3-1,6-glucan powder, an inclusion complex, a method for producing the inclusion complex, and a method for recovering a guest molecule. The ?-1,3-1,6-glucan powder has a saturation solubility in water at 25° C. of from 1.0 to 20.0 % by mass. The ?-1,3-1,6-glucan powder is such that in a particle size distribution of ?-1,3-1,6-glucans, determined by subjecting the ?-1,3-1,6-glucan powder to dynamic light scattering measurements, a particle size of a peak representing a largest volume fraction is in a range from 5 nm to 15 nm, and a volume fraction of a peak outside of the particle size range from 5 nm to 15 nm is 30 % or less of the volume fraction of the peak having the largest volume fraction.Type: GrantFiled: October 10, 2018Date of Patent: July 12, 2022Assignees: MITSUBISHI GAS CHEMICAL COMPANY, INC., KONAN GAKUENInventors: Yoshitaka Kitahara, Kazuya Koumoto
-
Publication number: 20200231709Abstract: Provided are a ?-1,3-1,6-glucan powder having high solubility in water, a glucan-containing composition using the powder or the like, a method for producing the ?3-1,6-glucan powder, an inclusion complex, a method for producing the inclusion complex, and a method for recovering a guest molecule. The ?-1,3-1,6-glucan powder has a saturation solubility in water at 25° C. of from 1.0 to 20.0 % by mass. The ?-1,3-1,6-glucan powder is such that in a particle size distribution of ?3-1,6-glucans, determined by subjecting the ?-1,3-1,6-glucan powder to dynamic light scattering measurements, a particle size of a peak representing a largest volume fraction is in a range from 5 nm to 15 nm, and a volume fraction of a peak outside of the particle size range from 5 nm to 15 nm is 30 % or less of the volume fraction of the peak having the largest volume fraction.Type: ApplicationFiled: October 10, 2018Publication date: July 23, 2020Applicants: MITSUBISHI GAS CHEMICAL COMPANY, INC., KONAN GAKUENInventors: Yoshitaka KITAHARA, Kazuya KOUMOTO
-
Publication number: 20110301230Abstract: Disclosed is a gene carrier composed of a hydrogen-bonding polymer having a polymer chain with hydrogen-bonding sites formed on the polymer chain, in which the polymer chain has a conformation similar to the conformation of a nucleic acid, and particularly, the polymer chain has helix parameters similar to the helix parameters of a nucleic acid of a helix structure. In a preferred embodiment, the hydrogen-bonding polymer is composed of ?-1,3-glucan such as schizophyllan. The carrier can be expected to be applied as a vector and a separator for nucleic acids because it is capable of interacting with a nucleic acid to form a complex with the nucleic acid and thus carrying the nucleic acid.Type: ApplicationFiled: August 22, 2011Publication date: December 8, 2011Applicants: TAITO CO., LTD, JAPAN SCIENCE AND TECHNOLOGY CORPORATIONInventors: Kazuo SAKURAI, Seiji Shinkai, Taro Kimura, Kengo Tabata, Kazuya Koumoto, Oliver Gronwald
-
Patent number: 8017742Abstract: Disclosed is a gene carrier composed of a hydrogen-bonding polymer having a polymer chain with hydrogen-bonding sites formed on the polymer chain, in which the polymer chain has a conformation similar to the conformation of a nucleic acid, and particularly, the polymer chain has helix parameters similar to the helix parameters of a nucleic acid of a helix structure. In a preferred embodiment, the hydrogen-bonding polymer is composed of ?-1,3-glucan such as schizophyllan. The carrier can be expected to be applied as a vector and a separator for nucleic acids because it is capable of interacting with a nucleic acid to form a complex with the nucleic acid and thus carrying the nucleic acid.Type: GrantFiled: June 19, 2003Date of Patent: September 13, 2011Assignees: Japan Science and Technology Agency, Mitsui Sugar Co., Ltd.Inventors: Kazuo Sakurai, Seiji Shinkai, Taro Kimura, Kengo Tabata, Kazuya Koumoto, Oliver Gronwald
-
Patent number: 7790189Abstract: Disclosed is a new type of immunostimulating agent including an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect. The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having ?-1,3-bonds (preferably ?-1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.Type: GrantFiled: May 13, 2004Date of Patent: September 7, 2010Assignees: Mitsui Sugar Co., Ltd., Japan Science and Technology AgencyInventors: Masami Mizu, Seiji Shinkai, Kazuo Sakurai, Kazuya Koumoto, Munenori Numata, Takahiro Matsumoto
-
Patent number: 7521433Abstract: Disclosed are gene carriers utilizing ?-1,3-glucan and methods of preparing the same. The ?-1,3-glucan has at least one 1,6-glucopyranoside branch and is chemically modified through periodate oxidation and reductive amination so as to impart nucleic acid-binding functional groups (for example, cationic functional groups) to at least some of the 1,6-glucopyranoside branches thereof. Triple helix ?-1,3-glucan is dissolved in a polar organic solvent to form single-stranded ?-1,3-glucan. By replacing, in the presence of a nucleic acid, the polar organic solvent for the solution containing the chemically modified single-stranded ?-1,3-glucan by water, a complex (gene carrier) is formed in which the nucleic acid is bound to double-stranded ?-1,3-glucan.Type: GrantFiled: March 11, 2002Date of Patent: April 21, 2009Assignees: Japan Science and Technology Agency, Mitsui Sugar Co., Ltd., Fukuoka Prefectural GovernmentInventors: Taro Kimura, Masami Mizu, Kazuo Sakurai, Seiji Shinkai, Kazuya Koumoto
-
Publication number: 20080262210Abstract: Disclosed is a new type of immunostimulating agent including an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect. The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having ?-1,3-bonds (preferably ?-1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.Type: ApplicationFiled: May 13, 2004Publication date: October 23, 2008Applicants: Mitsui Sugar Co., Ltd., Japan Science and Technology AgencyInventors: Masami Mizu, Seiji Shinkai, Kazuo Sakurai, Kazuya Koumoto, Munenori Numata, Takahiro Matsumoto
-
Publication number: 20060084149Abstract: Disclosed are gene carriers utilizing ?-1,3-glucan and methods of preparing the same. The ?-1,3-glucan has at least one 1,6-glucopyranoside branch and is chemically modified through periodate oxidation and reductive amination so as to impart nucleic acid-binding functional groups (for example, cationic functional groups) to at least some of the 1,6-glucopyranoside branches thereof. Triple helix ?-1,3-glucan is dissolved in a polar organic solvent to form single-stranded ?-1,3-glucan. By replacing, in the presence of a nucleic acid, the polar organic solvent for the solution containing the chemically modified single-stranded ?-1,3-glucan by water, a complex (gene carrier) is formed in which the nucleic acid is bound to double-stranded ?-1,3-glucan.Type: ApplicationFiled: March 11, 2002Publication date: April 20, 2006Inventors: Taro Kimura, Masami Mizu, Kazuo Sakurai, Seiji Shinkai, Kazuya Koumoto
-
Publication number: 20030216346Abstract: Disclosed is a gene carrier composed of a hydrogen-bonding polymer having a polymer chain with hydrogen-bonding sites formed on the polymer chain, in which the polymer chain has a conformation similar to the conformation of a nucleic acid, and particularly, the polymer chain has helix parameters similar to the helix parameters of a nucleic acid of a helix structure. In a preferred embodiment, the hydrogen-bonding polymer is composed of &bgr;-1,3-glucan such as schizophyllan. The carrier can be expected to be applied as a vector and a separator for nucleic acids because it is capable of interacting with a nucleic acid to form a complex with the nucleic acid and thus carrying the nucleic acid.Type: ApplicationFiled: June 19, 2003Publication date: November 20, 2003Applicants: TAITO CO. LTD, a Japanese corporation, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, a Japanese corporationInventors: Kazuo Sakurai, Seiji Shinkai, Taro Kimura, Kengo Tabata, Kazuya Koumoto, Oliver Gronwald